IMR Press / FBL / Volume 18 / Issue 1 / DOI: 10.2741/4104

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Novel immunoregulatory properties of EGCG on reducing inflammation in EAE
Show Less
1 Shanghai Institute of Immunology, Institutes of Medical Sciences, Shanghai JiaoTong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China
2 Department of Neurosurgery, the Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Street, Harbin 150001, China
3 Department of Clinical Laboratory, Shenzhen Children's Hospital, 7019 Yitian Road, Shenzhen 518026, China
4 Institute of Health Sciences, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences, 225 South Chongqing Road, Shanghai 200025, China
Academic Editor:Tong Zhou
Front. Biosci. (Landmark Ed) 2013, 18(1), 332–342; https://doi.org/10.2741/4104
Published: 1 January 2013
(This article belongs to the Special Issue Immune pathology)
Abstract

EGCG is one of the major catechins in green tea. In this study, we investigated the novel regulatory mechanism of EGCG on amelioration of experimental autoimmune encephalomyelitis (EAE). The data showed that EGCG reduced disease severity in EAE by decreasing brain inflammation and demyelination damage, accompanied by decreased encephalitogenic T cell responses and reduced expression of inflammatory cytokines and chemokines. The effect of EGCG was attributable to its selective inhibition of interferon-gamma and interleukin-17 production in CD4+ T cells, mediated via alteration of the STAT pathway and the transcription factors T-bet and retinoid-related orphan receptor (ROR) gammat/ROR alpha. More important, EGCG has been found novel properties of directly inhibiting Th1 and Th17 cell differentiation in this study. On the other hand, EGCG-treated antigen presenting cells (APC) exhibited reduced costimulatory function as a result of altered expression of CD80 and CD86. The results of this study indicate that EGCG is a novel anti-inflammatory agent that could act as a useful drug for the treatment of multiple sclerosis and other neuroinflammatory diseases in the further.

Keywords
EGCG
Th1
Th17
APC
Experimental Autoimmune Encephalomyelitis
Share
Back to top